Biography:Chelsea Pinnix
Chelsea Camille Pinnix | |
|---|---|
| Alma mater | University of Maryland, Baltimore County University of Pennsylvania |
| Scientific career | |
| Institutions | MD Anderson Cancer Center |
| Thesis | Notch1 activation confers transforming properties to primary human melanocytes and promotes human melanoma progression (2006) |
Chelsea Camille Pinnix is an American oncologist who is an Associate Professor of Radiation Oncology and Director of the Residency Program at the MD Anderson Cancer Center (MDACC). Having joined the faculty 2012, her research looks to improve the outcomes of patients who suffer from lymphoma.[1][2][3]
Pinnix attended the University of Maryland, Baltimore County for her undergraduate degree, where she studied biochemistry. She was a member of the Meyerhoff Scholarship Program.[4] She moved to the University of Pennsylvania for her medical degree, and completed an MD-PhD in 2007.[1] She was awarded a National Institutes of Health Medical Science Scholarship and the NIH Ruth L. Kirschstein National Research Service Award.[4] In 2010 she was supported by the UNCF to complete postdoctoral research at the MDACC.[5]
Selected publications
References
- ↑ 1.0 1.1 "Chelsea C. Pinnix" (in en). https://faculty.mdanderson.org/profiles/chelsea_pinnix.html.
- ↑ "Here's What Radiation Is Like for Non-Hodgkin Lymphoma" (in en-US). https://www.survivornet.com/articles/heres-what-radiation-is-like-for-non-hodgkin-lymphoma/.
- ↑ "Radiation May Be a Useful Bridging Therapy to CAR-T Treatment in Relapsed/Refractory Non-Hodgkin Lymphoma" (in en-US). 2020-10-28. https://www.cancertherapyadvisor.com/home/cancer-topics/lymphoma/lymphoma-cart-therapy-radiation-toxicity-risk/.
- ↑ 4.0 4.1 "Chelsea Pinnix (M7)" (in en). https://meyerhoff.umbc.edu/chiatogu-onyewu-m7/.
- ↑ "Chelsea Pinnix, MD-PhD". https://leadershipalliance25.files.wordpress.com/2018/05/cp.pdf.
 |  |
